Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9345 - 9352 of 12089 results
Purchaser of LLC Units May Enforce Non-Compete Without Employee Consent
July 9, 2015| Blog| Viewpoint
Busy July for Congress as Obama Lays Groundwork for Global Climate Summit
July 9, 2015| Blog| Viewpoint
Final Drug Shortage Reporting Rules Will Go Into Effect September 2015
July 9, 2015| Blog| Viewpoint
Investors That Agree to Rely on Their Own Due Diligence May Be Held to That Promise
July 8, 2015| Blog| Viewpoint
Second Circuit Continues the Ebook Saga by Affirming Apple’s Role in an Unlawful Price Fixing Conspiracy
July 8, 2015| Alert| Viewpoint
The 3rd Annual GREAT Tech Awards – Apply Now!
July 8, 2015| Blog| Viewpoint
Sunlight is the best disinfectant: SEC charges oil company for fraud on EB-5 investors
July 8, 2015| Blog| Viewpoint
Recent SEC action against Luca Funds highlights perils of EB-5 deals for investors
July 8, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|